Personalised adjunctive anti-inflammatory therapy to reduce deaths from tuberculosis. (360G-Wellcome-110179_Z_15_Z)

£2,563,000

A. In HIV-uninfected individuals with tuberculous meningitis: 1. Should adjunctive corticosteroid treatment be personalised according to LTA4H genotype? 2. Are there additional host-derived genotypic or phenotypic predictors of corticosteroid treatment response? 3. Do host-derived genotypic and phenotypic predictors of corticosteroid response in Vietnamese people apply to different populations? B. In HIV-infected individuals with tuberculous meningitis: 4. Is there benefit from adjunctiv e corticosteroids and are there host-derived genotypic and phenotypic predictors of treatment response? C. In HIV-uninfected and HIV-infected individuals with pulmonary tuberculosis: 5. Do LTA4H genotype and other genotypic and/or phenotypic predictors of tuberculous meningitis treatment response identified from Questions A2 and B4 predict clinical phenotype, response to treatment and outcome?

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 2563000
Applicant Surname Thwaites
Approval Committee Science Interview Panel
Award Date 2015-12-02T00:00:00+00:00
Financial Year 2015/16
Grant Programme: Title Investigator Award in Science
Internal ID 110179/Z/15/Z
Lead Applicant Prof Guy Thwaites
Partnership Value 2563000
Planned Dates: End Date 2024-03-31T00:00:00+00:00
Planned Dates: Start Date 2016-04-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region South East